SEC Form 4			_			_		_		_	_		_					
FORM 4 UNITED			D STA	D STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL		
Section 16. Form 4 or Form 5 obligations may continue. See					NT OF CHANGES IN BENEFICIAL OWNER d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940										HIP OMB Number: 3235-0287 Estimated average burden hours per response: 0.5			
1. Name and Address of Reporting Person <sup>*</sup> Wolchko J Scott				FATE THERAPEUTICS INC [ FATE ] (Check all applied X Director)   X Director)										r 10% Owner (give title Other (specify			ner	
	) (First) (Middle) FATE THERAPEUTICS, INC. 78 SCRIPPS SUMMIT DRIVE				3. Date of Earliest Transaction (Month/Day/Year) 11/18/2021									A below)		President and CEO		
(Street) SAN DIEGO CA 92131				Line)										iled by One	bint/Group Filing (Check Applicable ed by One Reporting Person ed by More than One Reporting			
(City)	(State)	(Zip) Fable I - No	n-Deriva	ative	e Se	curit	ies Ac	quired,	Dis	posed o	of, o	r Ben	eficial	ly Owned				
Date				2. Transaction Date (Month/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (	Transaction Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			Benefici Owned F	es ally Following	Form (D) o	r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership
								Code	v	Amount		(A) or (D)	Price	Reporter Transact (Instr. 3	tion(s)			(Instr. 4)
Common Stock	11/18/2021		1			<b>M</b> <sup>(1)</sup>		20,000		Α	\$2.7	413	413,793		D			
Common Stock	11/18/2021		1			<b>S</b> <sup>(1)</sup>		20,000		D	\$54.2	.7 393	3,793		D			
Common Stock 1				11/19/2021				A <sup>(2)</sup>		86,475		А	\$0.0	3 480	),268		D	
		Table II -						,		osed of, convertil			-	Owned				
1. Title of Derivative Security (Instr. 3) 2. Conversia or Exerci: Price of Derivative Security	se (Month/Day/Ye	ar) if any	A. Deemed 4. A. Deemed 4.		ansaction ode (Instr. Secu Acqu (A) o Dispu of (D		umber vative urities uired	6. Date Expiration (Month/Da	xercis n Date ay/Ye	able and	7. Title and An of Securities Underlying Derivative Sec (Instr. 3 and 4)		Amount s Security 1 4) Amount or Number	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti (Instr. 4)	e s dly g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
Stock		_	C	ode	v	(A)	(D)	Exercisat		Date	Title		Shares	<u> </u>				

Explanation of Responses:

\$<mark>2.7</mark>

1. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 10, 2020.

2. These shares were granted pursuant to a performance-based restricted stock unit award. The units will vest in three approximately equal installments conditioned upon the achievement, on or before December 31, 2026, of up to three specified late-stage clinical and regulatory milestones of the issuer, so long as the reporting person continues to serve as an employee of the issuer through each milestone achievement.

(3)

20,000

3. This option is fully vested.

(right to buy)

**Remarks:** 

/s/ Cindy Tahl, Attorney-in-Fact

11/22/2021

79,446

D

\*\* Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $\ast$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

11/18/2021

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

**M**<sup>(1)</sup>

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Date

20,000

\$0.00

Stock

01/11/2026